Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 18 peer-reviewed journal articles Updated

Treatment Transitions: Managing Your Bone Health Long-Term

At a Glance

Drug-induced osteoporosis treatment should be changed with a plan, not stopped suddenly. Denosumab must stay on schedule or be followed by a bisphosphonate to reduce rapid bone loss and spine fractures; high-risk patients may need bone-building therapy followed by maintenance treatment.

Managing bone health is not just about starting a medication; it is about orchestrating a careful sequence of treatments over years or decades. Because different medications work in different ways, “switching” or “stopping” them requires a precise strategy to avoid losing the bone you have worked hard to build [1][2].

The Denosumab ‘Rebound’ Warning

Denosumab (Prolia) is a highly effective injection given every 6 months that stops bone-destroying cells [3]. However, unlike other medications, its effects disappear rapidly once the drug leaves your system [4].

The Risk: If you stop denosumab or experience an extended gap between doses, your bone turnover markers can “rebound” to levels much higher than before you started treatment [4][4]. This causes a rapid loss of bone density within just 6 to 12 months [5]. Most dangerously, this rebound is linked to a high risk of multiple vertebral fractures [4][6].

The Strategy:

  • Keep on Schedule: Injections should be kept on a 6-month schedule. If a delay beyond roughly 7 months occurs, contact your clinician promptly.
  • The Transition: Denosumab must never be discontinued without a “relay” or “bridge” plan [7]. To “lock in” the bone gains, you must transition to a bisphosphonate (like alendronate or zoledronic acid) approximately around the time your next denosumab injection was due [7][8].
  • Monitoring: Your doctor may check your bone turnover markers (blood tests like CTX) to ensure the transition is successfully keeping bone loss at bay [9][7].

Sequential Therapy: Building Then Protecting

For selected patients at very high risk—such as those on high-dose steroids or with multiple past fractures—doctors may conditionally consider sequential therapy. This means using a “bone-builder” first, followed by a “bone-maintainer” [1][10].

  1. Anabolic Agents (The Builders): Medications like teriparatide or abaloparatide are used for up to 24 months, while romosozumab is generally limited to 12 months, to rapidly increase bone mass and improve architecture [1][11]. (Note: In the U.S., romosozumab carries a boxed warning and is contraindicated if you have had a myocardial infarction or stroke within the preceding year) [12].
  2. Antiresorptives (The Maintainers): Because the gains from anabolics are lost quickly after you stop, you must follow them with a bisphosphonate or denosumab to consolidate and protect the new bone [13][2].

Important Note: Starting with a “builder” typically produces better results than trying to use one after years of “maintainer” therapy [13][14].

Bisphosphonate Holidays

Bisphosphonates (like Fosamax or Reclast) are unique because they “bind” to your bone and stay there for years, even after you stop taking them [15]. This allows some patients to consider a drug holiday—a temporary pause in treatment [16].

  • Why take a holiday?: While rare, long-term use (typically over 3-5 years) is associated with two specific risks: Atypical Femoral Fractures (AFF) (stress fractures in the thigh bone) and Medication-Related Osteonecrosis of the Jaw (ONJ) (healing issues in the jawbone). Note that ONJ is much more strongly associated with high-dose oncology regimens than standard osteoporosis doses [17][15][18].
  • Who is eligible?: A holiday may be considered for selected low-to-moderate-risk patients who have completed 3 to 5 years of treatment and whose T-scores and fracture risks have improved [15].
  • Who should continue?: A holiday is an option, not a requirement. If you are at “high risk” or are currently taking high doses of glucocorticoids, you may need to continue treatment, as the risk of a typical fracture is far higher than the risk of rare side effects [15][16].

Summary of Medication Classes

Class Examples Role Key Consideration
Bisphosphonates Alendronate, Zoledronic Acid Maintenance Holidays may be considered for select patients after long-term use [15].
RANKL Inhibitors Denosumab Potent Protection Crucial: Stay on schedule; needs transition plan if stopped [4].
Anabolics Teriparatide, Abaloparatide Bone Building Used first for selected high-risk patients; 24-month limit [1].
Sclerostin Inhibitors Romosozumab Building/Maintenance Dual action; 12-month limit. Avoided if history of recent stroke/heart attack [12].

Common questions in this guide

What can happen if I miss or stop a denosumab injection?
Denosumab's effects can wear off quickly after a missed or stopped dose. The body may break down bone much faster, causing rapid bone loss within 6 to 12 months and raising the risk of several spine fractures. Contact your clinician promptly if an injection will be delayed, especially beyond about 7 months.
Do I need another osteoporosis medicine when stopping denosumab?
Usually, denosumab should not be stopped without a follow-up plan. A bisphosphonate such as alendronate or zoledronic acid is often given around the time the next denosumab injection would have been due to help preserve bone gains. The exact medicine and timing depend on your fracture risk and should be set by your clinician.
Could bone-building treatment be started before my maintenance medicine?
Some people at very high fracture risk, including those taking high-dose steroids or with several previous fractures, may be candidates for a bone-building medicine first. Teriparatide or abaloparatide can be used for up to 24 months, while romosozumab is generally limited to 12 months. A bisphosphonate or denosumab is then used to help maintain the new bone. In the United States, romosozumab should not be used if you had a heart attack or stroke within the previous year.
What is a bisphosphonate drug holiday, and who may qualify?
A drug holiday is a planned temporary pause after a period of bisphosphonate treatment, not an automatic step for everyone. It may be considered after about 3 to 5 years for selected people whose bone density and fracture risk have improved. People at high fracture risk or taking high-dose glucocorticoids may be safer continuing treatment.
What are the rare risks of long-term bisphosphonate use?
Long-term bisphosphonate use is associated with rare atypical femoral fractures, which are stress fractures in the thigh bone, and medication-related osteonecrosis of the jaw, a jaw-healing problem. Jaw osteonecrosis is much more strongly associated with high-dose cancer treatment than with standard osteoporosis doses. Your clinician weighs these uncommon risks against your risk of a typical fracture.
How will my doctor monitor a medication transition?
Your clinician may use blood tests such as CTX or PINP to see whether bone breakdown is being controlled after a treatment change. A bone-density scan called a DXA may also be scheduled to reassess bone density, especially during a bisphosphonate holiday. Monitoring schedules depend on the medicines and your fracture risk.
How should I take an oral bisphosphonate?
Take it on an empty stomach with a full glass of water, and remain upright for the time specified for your product. Follow the label and your clinician's instructions because timing requirements can differ by medicine. Ask before changing how you take it.

Get notified when new evidence is published on drug-induced osteoporosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    The Anabolic-First Strategy in Osteoporosis: A Systematic Review and Meta-Analysis of Fracture Outcomes in Patients at Very High Fracture Risk.

    Cipolloni V, Bonifacio M, Hassny SM, et al.

    Medicina (Kaunas, Lithuania) 2026; (62(4)) doi:10.3390/medicina62040687.

    PMID: 42075559
  2. 2

    Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).

    Leder BZ, Tsai JN, Jiang LA, Lee H

    Bone 2017; (98()):54-58 doi:10.1016/j.bone.2017.03.006.

    PMID: 28286299
  3. 3

    Mind the gap: Adherence to denosumab dosing and cessation guidelines in Australian residential aged care.

    O'Donnell M, Westbrook JI, Rahman B, et al.

    British journal of clinical pharmacology 2026; (92(8)):2819-2827 doi:10.1002/bcp.70574.

    PMID: 42026907
  4. 4

    Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.

    Cummings SR, Ferrari S, Eastell R, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2018; (33(2)):190-198 doi:10.1002/jbmr.3337.

    PMID: 29105841
  5. 5

    Denosumab Discontinuation.

    Sølling AS, Tsourdi E, Harsløf T, Langdahl BL

    Current osteoporosis reports 2023; (21(1)):95-103 doi:10.1007/s11914-022-00771-6.

    PMID: 36564572
  6. 6

    Potent bisphosphonate therapy for preventing fractures after denosumab discontinuation in osteoporosis: A GRADE-assessed systematic review and meta-analysis.

    Shah A, Khan S, Rizvi SVZ, et al.

    Medicine 2026; (105(36)):e50542 doi:10.1097/MD.0000000000050542.

    PMID: 42700089
  7. 7

    Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS.

    Tsourdi E, Zillikens MC, Meier C, et al.

    The Journal of clinical endocrinology and metabolism 2020; doi:10.1210/clinem/dgaa756.

    PMID: 33103722
  8. 8

    Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.

    Tsourdi E, Langdahl B, Cohen-Solal M, et al.

    Bone 2017; (105()):11-17 doi:10.1016/j.bone.2017.08.003.

    PMID: 28789921
  9. 9

    The Role of PINP in Diagnosis and Management of Metabolic Bone Disease.

    Gillett MJ, Vasikaran SD, Inderjeeth CA

    The Clinical biochemist. Reviews 2021; (42(1)):3-10 doi:10.33176/AACB-20-0001.

    PMID: 34305208
  10. 10

    The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence.

    Chandran M

    Archives of endocrinology and metabolism 2022; (66(5)):724-738.

    PMID: 36382762
  11. 11

    Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatide.

    Cosman F, Mitlak BH, Wang Y, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2025; (40(6)):773-778 doi:10.1093/jbmr/zjaf053.

    PMID: 40214193
  12. 12

    Bone Anabolic Treatment in Older Subjects: A Narrative Review.

    Hadzimuratovic B, Mattes D, Haschka J, Kocijan R

    Gerontology 2025; (71(10)):842-851 doi:10.1159/000547313.

    PMID: 40652924
  13. 13

    Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.

    Langdahl B

    Bone 2020; (139()):115516 doi:10.1016/j.bone.2020.115516.

    PMID: 32622871
  14. 14

    Romosozumab and antiresorptive treatment: the importance of treatment sequence.

    Cosman F, Kendler DL, Langdahl BL, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2022; (33(6)):1243-1256 doi:10.1007/s00198-021-06174-0.

    PMID: 35165774
  15. 15

    Bisphosphonate Drug Holidays in Primary Care: When and What to Do Next?

    Bauer DC, Abrahamsen B

    Current osteoporosis reports 2021; (19(2)):182-188 doi:10.1007/s11914-021-00660-4.

    PMID: 33528743
  16. 16

    Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday.

    Villa JC, Gianakos A, Lane JM

    HSS journal : the musculoskeletal journal of Hospital for Special Surgery 2016; (12(1)):66-73 doi:10.1007/s11420-015-9469-1.

    PMID: 26855630
  17. 17

    Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.

    Black DM, Geiger EJ, Eastell R, et al.

    The New England journal of medicine 2020; (383(8)):743-753 doi:10.1056/NEJMoa1916525.

    PMID: 32813950
  18. 18

    Diagnosis and Management of Atypical Femoral Fractures and Medication-Related Osteonecrosis of the Jaw in Patients with Osteoporosis.

    Alnajmi RAY, Ali DS, Khan AA

    Endocrinology and metabolism clinics of North America 2024; (53(4)):607-618 doi:10.1016/j.ecl.2024.08.007.

    PMID: 39448140

This page is for informational purposes only and does not constitute medical advice. Do not delay or stop osteoporosis treatment without speaking with your prescriber about your individual fracture risk and transition plan.

Guide contents drug-induced osteoporosis
Research & Literature
04 Standard of Care 06 Long-Term Monitoring